RIP 2 FAF

Related

• 

  Baseline Factors Associated With 1-Year Outcomes in Phase III Comparison of SB11 (Approved Ranibizumab Biosimilar) With Reference Ranibizumab in nAMD

  Neil M. Bressler, MD

  Annual Meeting Talks

  2022

• 

  ICG: Choroidal Aspergilloma With Secondary Choroidal Neovascularization and Exudative Retinal Detachment

  Scott D Walter, MD, MSc, FASRS

  Retina Image Bank: Images of the Week

• 

  Primary Analysis Results of the Phase 3 Archway Trial of the Port Delivery System With Ranibizumab (PDS) for Patients With Neovascular AMD

  Peter A. Campochiaro, MD

  Annual Meeting Talks

  2020